TrialsgrambetaRCTs are beautiful

Atrial fibrillation

Rate versus rhythm, NOAC trials, ablation and pulsed-field ablation.

  • 2025OPTION⁠LAAOIn 1,600 patients with atrial fibrillation who underwent catheter ablation, left atrial appendage closure was non-inferior for death, stroke, or systemic embolism and reduced bleeding compared with oral anticoagulation.5.3% vs 5.8%Read →
  • 2025OCEANIC-AF⁠factor XIa inhibitorIn 14,810 patients with atrial fibrillation at high stroke risk, asundexian was inferior for prevention of stroke or systemic embolism compared with apixaban.HR 3.7995% CI 2.46-5.83Read →
  • 2024ARTESiA⁠DOACIn 4,012 patients with device-detected subclinical AF and stroke risk factors, apixaban reduced stroke or systemic embolism compared with aspirin, at the cost of more bleeding.HR 0.6395% CI 0.45-0.88Read →
  • 2024FRAIL-AF⁠DOAC switchIn 1,330 frail elderly patients with atrial fibrillation stable on a vitamin K antagonist, switching to a DOAC increased major or clinically relevant bleeding compared with continuing the vitamin K antagonist.HR 1.6995% CI 1.23-2.32Read →
  • 2024SHAM-PVI Core⁠AblationIn 126 patients with symptomatic paroxysmal or persistent atrial fibrillation, cryoballoon pulmonary vein isolation reduced atrial fibrillation burden at 6 months compared with a sham procedure.60.3% vs 35.0%Read →
  • 2023ADVENT⁠AblationIn 607 patients with paroxysmal AF, pulsed-field ablation was non-inferior to conventional thermal ablation for treatment success and safety.73.3% vs 71.3%Read →
  • 2023NOAH-AFNET 6⁠DOACIn 2,536 patients with device-detected atrial high-rate episodes, edoxaban did not reduce cardiovascular death, stroke, or systemic embolism compared with placebo.HR 0.8195% CI 0.60-1.08Read →
  • 2021EARLY-AF⁠AblationIn 303 patients with paroxysmal AF, first-line cryoballoon ablation reduced atrial arrhythmia recurrence compared with antiarrhythmic drugs.HR 0.48Read →
  • 2021LAAOS III⁠surgical LAAOIn 4,660 patients with atrial fibrillation undergoing cardiac surgery, surgical left atrial appendage occlusion reduced ischaemic stroke or systemic embolism compared with no occlusion.HR 0.6795% CI 0.53-0.85Read →
  • 2020EAST-AFNET 4⁠Rate vs rhythmIn 2,789 patients with early AF (≤ 1 yr), early rhythm-control therapy reduced CV death, stroke or hospitalisation for HF or ACS versus usual care.HR 0.79Read →
  • 2020PRAGUE-17⁠LAAOIn 402 high-risk patients with non-valvular atrial fibrillation, percutaneous left atrial appendage closure was non-inferior for a composite of cardiovascular and bleeding events compared with direct oral anticoagulants.HR 0.8495% CI 0.53-1.31Read →
  • 2019CABANA⁠AblationIn 2,204 patients with symptomatic atrial fibrillation, catheter ablation did not significantly reduce death, disabling stroke, serious bleeding, or cardiac arrest compared with antiarrhythmic drug therapy.HR 0.8695% CI 0.65-1.15Read →
  • 2018CASTLE-AF⁠AblationIn 363 patients with AF and heart failure with reduced ejection fraction, catheter ablation reduced death or heart-failure hospitalisation compared with medical therapy.HR 0.62Read →
  • 2016FIRE AND ICE⁠AblationIn 762 patients with drug-refractory paroxysmal atrial fibrillation, cryoballoon ablation was non-inferior for clinical treatment failure compared with radiofrequency ablation.HR 0.9695% CI 0.76-1.22Read →
  • 2015STAR AF II⁠AblationIn 589 patients with persistent atrial fibrillation, adding complex electrogram or linear ablation did not improve freedom from AF recurrence compared with pulmonary-vein isolation alone.Read →
  • 2014PROTECT AF⁠LAAOIn 707 patients with non-valvular atrial fibrillation eligible for warfarin, Watchman left atrial appendage closure was non-inferior for stroke, systemic embolism, or cardiovascular death compared with warfarin.IRR 0.6095% CI 0.41-1.05Read →
  • 2014CRYSTAL AF⁠cardiac monitorIn 441 patients with recent cryptogenic stroke, an insertable cardiac monitor detected atrial fibrillation more often than conventional follow-up.HR 6.495% CI 1.9-21.7Read →
  • 2013ENGAGE AF-TIMI 48⁠AnticoagulationIn 21,105 patients with AF at moderate-to-high stroke risk, edoxaban was non-inferior to warfarin for stroke or systemic embolism, with less bleeding.Read →
  • 2011ROCKET-AF⁠AnticoagulationIn 14,264 patients with non-valvular AF at moderate-high stroke risk, rivaroxaban was non-inferior to warfarin for stroke or systemic embolism, with less intracranial bleeding.Read →
  • 2011ARISTOTLE Core⁠AnticoagulationIn 18,201 patients with AF and ≥ 1 stroke risk factor, apixaban reduced stroke or systemic embolism, major bleeding and all-cause mortality compared with warfarin.Read →
  • 2010RACE II⁠rate controlIn 614 patients with permanent atrial fibrillation, lenient rate control (resting heart rate <110 bpm) was non-inferior for a composite of cardiovascular events compared with strict rate control.12.9% vs 14.9%Read →
  • 2009RE-LY Core⁠AnticoagulationIn 18,113 patients with non-valvular AF, dabigatran 150 mg twice daily reduced stroke or systemic embolism compared with warfarin, with similar major bleeding.RR 0.66Read →
  • 2002AFFIRM⁠Rate vs rhythmIn 4,060 patients with AF at high risk of stroke, a rhythm-control strategy did not reduce all-cause mortality compared with rate control.HR 1.1595% CI 0.99-1.34Read →
  • 1991SPAF⁠antithromboticIn 1,330 patients with non-rheumatic atrial fibrillation, warfarin and aspirin each reduced ischaemic stroke or systemic embolism compared with placebo.Read →